載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.4602
−US$0.0635 · -12.13%
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
最新資料
US$0.4602
−US$0.0635 · -12.13%
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
46
合理估值
情緒
55
多空交錯
風險
70
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年4月6日 | 1:5 | — | — |
股票分割 | 2025年7月31日 | 1:10 | — | — |
股票分割 | 2024年10月4日 | 1:25 | — | — |
股票分割 | 2023年7月5日 | 1:80 | — | — |
股票分割 | 2023年3月27日 | 1:4 | — | — |
股票分割 | 2022年9月26日 | 1:5 | — | — |
已生效 2026年4月6日
1:5
已生效 2025年7月31日
1:10
已生效 2024年10月4日
1:25
已生效 2023年7月5日
1:80
已生效 2023年3月27日
1:4
已生效 2022年9月26日
1:5
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
